Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 18/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 15/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 6/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.38 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16668608 | 0.95 | CXCR4 (0.36) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL279379 | 0.82 | CXCR4 (0.42) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4530325 | 0.78 | ITGAV (0.43) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL19544248 | 0.78 | CXCR4 (0.39) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL8354537 | 0.76 | ITGAV (0.41) | CXCR4ITGAVITGB3ITGB6ITGB8 | |
| SCHEMBL28728264 | 0.76 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL21715684 | 0.75 | ITGAV (0.40) | CXCR4ITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL4762028 | 0.75 | ITGB3 (0.50) | ITGAVITGB3ITGB6ITGB5ITGB8 | |
| SCHEMBL22807265 | 0.74 | UHRF1 (0.64) | — | |
| SCHEMBL16668121 | 0.74 | ALDH1A1 (0.37) | ITGAVITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003400-B | 2-Formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024083086-A1 | BICYCLIC DERIVATIVE INTEGRIN INHIBITOR | 上海如凌生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117903171-A | Integrin inhibitors of a class of bicyclic derivatives | 上海如凌生物医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-116003400-A | 2-formyl tetrahydronaphthyridine compound and medicinal composition and application thereof | 暨南大学 | 2023-04-25 | — | — | CN | disclosed |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-21 | — | — | US | disclosed |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | TERNS PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-113234072-B | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113105454-B | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | PAYNE LINDA S (US) | 2003-12-11 | — | — | US | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1196384-A4 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO INC (US) | 2002-10-23 | — | — | EP | disclosed |
| EP-1196384-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | Merck & Co., Inc. (US) | 2002-04-17 | — | — | EP | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6211184-B1 | TETRAHYDRO-PYRAZINE OR PYRIMIDINE DERIVATIVES; VITRONECTIN RECEPTOR ANTAGONIST; OSTEOPOROSIS; ANTIINFLAMMATORY, ANTITUMOR AGENTS; ANGIOGENESIS AND RESTENOSIS INHIBITORS | MERCK & CO., INC. | 2001-04-03 | — | — | US | disclosed |
| WO-2001000578-A1 | 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5981546-A | Integrin antagonists | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | CXCR4 1439/4885ITGAV 2762/4885ITGB3 3611/4885 |
| US-20030229079-A1 | 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof | CYP2S1, IMPDH1, IDO1 | CXCR4 2626/4885ITGAV 4174/4885ITGB3 2550/4885 |
| US-11608332-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | CXCR4 1917/4885ITGAV 4004/4885ITGB3 3836/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | CXCR4 35/4885ITGAV 1/4885ITGB3 2/4885 |
| US-20220362245-A1 | COMPOUNDS FOR INHIBITING FGFR4 | FGFR4, FGFR1, FGFR3 | CXCR4 2348/4885ITGAV 4306/4885ITGB3 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.